Morgan Stanley’s Akso Health Group AHG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.1K Buy
+739
New +$1.33K ﹤0.01% 7500
2023
Q3
Sell
-3,370
Closed -$1.18K 7615
2023
Q2
$1.18K Hold
3,370
﹤0.01% 7275
2023
Q1
$1.2K Hold
3,370
﹤0.01% 7328
2022
Q4
$1.27K Hold
3,370
﹤0.01% 7438
2022
Q3
$3K Hold
3,370
﹤0.01% 7363
2022
Q2
$3K Sell
3,370
-9,188
-73% -$10.4K ﹤0.01% 7495
2022
Q1
$21K Sell
12,558
-900
-7% -$1.43K ﹤0.01% 7121
2021
Q4
$22K Buy
13,458
+8,871
+193% +$32.9K ﹤0.01% 7181
2021
Q3
$10K Hold
4,587
﹤0.01% 7311
2021
Q2
$7K Hold
4,587
﹤0.01% 7307
2021
Q1
$8K Sell
4,587
-400
-8% -$903 ﹤0.01% 7002
2020
Q4
$12K Sell
4,987
-1,000
-17% -$2.21K ﹤0.01% 6580
2020
Q3
$9K Buy
5,987
+4,964
+485% +$11K ﹤0.01% 6293
2020
Q2
$2K Buy
+1,023
New +$1.8K ﹤0.01% 6430
2018
Q2
Sell
-100
Closed -$3K 6653
2018
Q1
$3K Buy
100
+89
+809% +$2.95K ﹤0.01% 6443
2017
Q4
$0 Buy
+11
New +$391 ﹤0.01% 6557

Other funds holding AHG

Morgan Stanley's AHG Position: Q2 2026 in Review

Morgan Stanley opened a new position in Akso Health Group (AHG) in Q2 2026: 739 shares worth $1.1K. The stake represents ﹤0.01% of the portfolio and ranks #7500 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in AHG as recently as Q2 2023.

Morgan Stanley first reported a position in AHG in Q4 2017 and has held it in 16 quarters since. The position peaked at $22K in Q4 2021. 9 funds tracked by Wall St. Rank hold AHG as of Q2 2026.

  • Morgan Stanley held 739 shares of Akso Health Group worth $1.1K as of Q2 2026.
  • Akso Health Group was a new Morgan Stanley position in Q2 2026.
  • Akso Health Group made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7500 holding.
  • Morgan Stanley first reported a position in Akso Health Group in Q4 2017 and has held it in 16 quarters since.
  • Morgan Stanley's Akso Health Group position peaked at $22K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Akso Health Group as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.